Beclomethasone dipropionate monohydrate - Generic Drug Details

What are the generic sources for beclomethasone dipropionate monohydrate and what is the scope of freedom to operate?

Beclomethasone dipropionate monohydrate is the generic ingredient in two branded drugs marketed by Glaxosmithkline and Schering, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for beclomethasone dipropionate monohydrate.

Summary for beclomethasone dipropionate monohydrate

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	3
Drug Master File Entries:	2
Raw Ingredient (Bulk) Api Vendors:	10
What excipients (inactive ingredients) are in beclomethasone dipropionate monohydrate?	beclomethasone dipropionate monohydrate excipients list
DailyMed Link:	beclomethasone dipropionate monohydrate at DailyMed

US Patents and Regulatory Information for beclomethasone dipropionate monohydrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BECONASE AQ	beclomethasone dipropionate monohydrate	SPRAY, METERED;NASAL	019389-001	Jul 27, 1987		DISCN	Yes	No
Schering	VANCENASE AQ	beclomethasone dipropionate monohydrate	SPRAY, METERED;NASAL	019589-001	Dec 23, 1987		DISCN	No	No
Schering	VANCENASE AQ	beclomethasone dipropionate monohydrate	SPRAY, METERED;NASAL	020469-001	Jun 26, 1996		DISCN	No	No

Beclomethasone Dipropionate Monohydrate: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Beclomethasone dipropionate monohydrate, a synthetic corticosteroid, maintains a stable market position due to its efficacy in treating inflammatory respiratory conditions. Its financial trajectory is influenced by generic competition, ongoing clinical research, and regulatory landscapes.

What is the Current Market Size and Projected Growth for Beclomethasone Dipropionate Monohydrate?

The global market for beclomethasone dipropionate monohydrate is estimated at approximately \$750 million in 2023. Projections indicate a compound annual growth rate (CAGR) of 3.5% from 2023 to 2028, reaching an estimated \$890 million by 2028. This growth is primarily driven by the increasing prevalence of allergic rhinitis and asthma worldwide, particularly in emerging economies [1].

Key market segments include:

• Respiratory Diseases: This is the dominant segment, accounting for over 85% of the market. It encompasses treatments for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
• Dermatological Conditions: A smaller but growing segment, utilizing topical formulations for eczema and psoriasis.

The market's expansion is also supported by increased healthcare spending and improved diagnostic capabilities, allowing for earlier and more accurate identification of eligible patients [2].

Who are the Key Manufacturers and Competitors in the Beclomethasone Dipropionate Monohydrate Market?

The market for beclomethasone dipropionate monohydrate is characterized by a significant presence of generic manufacturers alongside a few innovator companies that hold original patents.

Major manufacturers include:

• GSK plc: The originator of beclomethasone dipropionate, with its primary brand QVAR (now discontinued in some regions and replaced by generics) [3].
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Mylan N.V. (now part of Viatris Inc.)
• Sanofi S.A.
• Cipla Ltd.
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.

Competition is intense, particularly in the generic space, which places downward pressure on pricing. Companies are focusing on developing differentiated formulations, such as metered-dose inhalers with improved delivery systems or combination therapies, to maintain market share and command premium pricing [4].

What are the Dominant Therapeutic Applications and Their Market Share?

The primary therapeutic applications for beclomethasone dipropionate monohydrate are rooted in its anti-inflammatory properties, making it a cornerstone for managing chronic respiratory inflammatory diseases.

Dominant therapeutic applications and their estimated market share:

• Asthma: Approximately 55% of the market. Beclomethasone dipropionate is a first-line treatment for persistent asthma, helping to control inflammation in the airways, reduce exacerbations, and improve lung function.
• Allergic Rhinitis: Approximately 25% of the market. Nasal spray formulations are widely used to alleviate symptoms such as sneezing, itching, nasal congestion, and runny nose.
• Chronic Obstructive Pulmonary Disease (COPD): Approximately 15% of the market. Inhaled corticosteroids like beclomethasone dipropionate are used in combination with long-acting bronchodilators for moderate to severe COPD to reduce airway inflammation and the frequency of exacerbations.
• Dermatological Conditions: Approximately 5% of the market. Topical creams and ointments are prescribed for inflammatory skin conditions like eczema and psoriasis.

The prevalence of respiratory diseases, compounded by factors like air pollution and smoking, ensures sustained demand for beclomethasone dipropionate in these applications [1, 2].

What is the Patent Landscape and Exclusivity Status for Beclomethasone Dipropionate Monohydrate?

The patent landscape for beclomethasone dipropionate monohydrate is largely mature, with primary patents having expired in most major markets. This has paved the way for extensive generic entry.

Key aspects of the patent landscape:

• Original Patents: The foundational patents for beclomethasone dipropionate itself have long expired. GSK plc, as the innovator, held early composition of matter and method of use patents.
• Formulation Patents: While the active pharmaceutical ingredient (API) is off-patent, some companies have secured patents for novel formulations, drug delivery devices, or manufacturing processes. These can provide limited periods of market exclusivity or act as barriers to entry for generic competitors attempting to replicate specific technologies. For example, patents relating to specific particle sizes or inhalation technologies for improved lung deposition could offer some protection.
• Exclusivity Periods: Regulatory exclusivities, such as data exclusivity and market exclusivity, are granted by regulatory bodies (e.g., FDA in the US, EMA in Europe) upon drug approval. These periods, distinct from patents, provide a block on regulatory approval for generic applications for a specified duration. For beclomethasone dipropionate, these exclusivities have also largely expired for the initial approvals.
• Generic Approvals: The market is characterized by numerous Abbreviated New Drug Applications (ANDAs) and their equivalents in other regions, leading to widespread availability of generic beclomethasone dipropionate products.

The absence of strong, remaining patent protection for the core compound means that pricing power is limited, and competition is primarily driven by manufacturing efficiency and market access [3, 5].

What are the Key Drivers and Restraints Affecting the Market?

The market dynamics for beclomethasone dipropionate monohydrate are shaped by a confluence of factors that promote its use while simultaneously posing challenges.

Key Drivers:

• Increasing Prevalence of Respiratory Diseases: A consistent rise in asthma and allergic rhinitis diagnoses globally, linked to environmental factors, urbanization, and lifestyle changes, directly fuels demand for effective inhaled corticosteroids [1, 2].
• Cost-Effectiveness of Generics: The availability of affordable generic versions makes beclomethasone dipropionate a highly accessible treatment option, particularly in healthcare systems with budget constraints and in emerging markets.
• Established Safety and Efficacy Profile: Decades of clinical use have established a well-understood safety and efficacy profile for beclomethasone dipropionate, making it a trusted choice for healthcare providers.
• Combination Therapies: The integration of beclomethasone dipropionate into fixed-dose combination inhalers (often with long-acting beta-agonists) for asthma and COPD management enhances its utility and market penetration [6].
• Technological Advancements in Drug Delivery: Innovations in inhaler devices, aiming for improved lung deposition and patient compliance, can revitalize market interest in existing molecules [4].

Key Restraints:

• Intense Generic Competition and Price Erosion: The mature patent landscape has led to a highly competitive generic market, resulting in significant price reductions and impacting revenue growth for individual manufacturers.
• Development of Novel Biologics and Advanced Therapies: The emergence of biologics and other advanced therapies for severe asthma and other inflammatory conditions offers alternative treatment paradigms, potentially diverting market share from traditional small molecules like beclomethasone dipropionate in specific patient populations.
• Stringent Regulatory Requirements: While the drug is well-established, ongoing regulatory scrutiny regarding manufacturing quality, adverse event reporting, and environmental impact can impose compliance costs.
• Potential for Systemic Side Effects: While generally well-tolerated when inhaled, corticosteroids carry a risk of systemic side effects with long-term, high-dose use, which can influence prescribing patterns, especially in favor of less systemic treatments where appropriate.

What is the Regulatory Landscape and its Impact on Beclomethasone Dipropionate Monohydrate?

The regulatory landscape plays a critical role in the market access, approval, and ongoing use of beclomethasone dipropionate monohydrate.

Key regulatory considerations:

• Approval Pathways: Beclomethasone dipropionate products are approved through established regulatory pathways for small molecule drugs. Generic versions require demonstration of bioequivalence to an approved reference listed drug.
• Pharmacovigilance and Post-Market Surveillance: Regulatory agencies worldwide (e.g., FDA, EMA, PMDA) mandate rigorous pharmacovigilance systems. Manufacturers must monitor and report adverse events, which can lead to label changes, warnings, or, in rare cases, market withdrawals if significant safety concerns arise [7].
• Quality Control and Manufacturing Standards: Compliance with Good Manufacturing Practices (GMP) is essential. Regulatory bodies conduct inspections to ensure that manufacturing processes consistently produce drugs of acceptable quality. Deviations can result in warning letters, import alerts, or product recalls.
• Labeling and Prescribing Information: Regulatory agencies approve the product labeling, including indications, contraindications, warnings, precautions, and dosage information. Any changes to these require regulatory approval and can impact market positioning.
• Environmental Regulations: Increasingly, pharmaceutical manufacturers face scrutiny and regulations related to the environmental impact of drug manufacturing and disposal. Compliance with these evolving standards is necessary.
• Generic Competition Policies: Regulatory frameworks designed to facilitate generic drug approvals are a significant factor, enabling the rapid market entry of multiple players once patents expire.

The regulatory environment ensures product safety and efficacy but also imposes compliance burdens and influences market entry and competition dynamics [5, 7].

What is the Financial Outlook and Investment Potential for Beclomethasone Dipropionate Monohydrate?

The financial outlook for beclomethasone dipropionate monohydrate is characterized by stable but moderate revenue generation, primarily within the generic pharmaceutical sector. Investment potential exists, but it is focused on specific niches rather than broad growth opportunities.

Financial outlook:

• Revenue Streams: The majority of revenue is generated from generic sales. Innovator companies that once held primary market share have seen their revenue streams shift towards other therapeutic areas or focus on remaining niche indications or patented formulations.
• Profit Margins: Generic manufacturers typically operate with lower profit margins compared to branded pharmaceuticals due to intense price competition. Success hinges on economies of scale, efficient manufacturing, and effective supply chain management.
• Investment Focus: Investment opportunities are more likely to be found in companies with strong generic manufacturing capabilities, specialized formulation technologies (e.g., advanced inhalation devices), or established distribution networks in emerging markets where demand for affordable respiratory treatments is growing.
• Research and Development: While significant R&D for new indications of beclomethasone dipropionate is unlikely, investment may occur in developing improved delivery systems or combination products that extend product life cycles or offer differentiated value.
• Mergers and Acquisitions (M&A): The market may see continued M&A activity as larger generic players seek to consolidate market share, acquire complementary product portfolios, or gain access to specific geographical regions.

The financial trajectory is steady, driven by consistent demand. However, substantial growth acceleration is not anticipated due to the drug’s mature life cycle and generic status.

Key Takeaways

• Beclomethasone dipropionate monohydrate is a mature pharmaceutical market with a stable financial trajectory, projected to reach \$890 million by 2028.
• Growth is primarily driven by the increasing prevalence of asthma and allergic rhinitis, coupled with the cost-effectiveness of generic formulations.
• The market is highly competitive, dominated by numerous generic manufacturers, with GSK plc as the originator.
• Respiratory conditions, particularly asthma, represent the largest therapeutic application, accounting for over 55% of the market.
• The patent landscape is largely depleted, leading to widespread generic availability and significant price erosion.
• Key restraints include intense generic competition, the emergence of novel therapies, and potential side effects.
• Regulatory compliance, particularly concerning GMP and pharmacovigilance, is crucial for all manufacturers.
• Investment potential lies in companies with strong generic manufacturing, specialized formulations, or emerging market presence.

Frequently Asked Questions

1. What is the primary mechanism of action for beclomethasone dipropionate monohydrate? Beclomethasone dipropionate monohydrate is a synthetic corticosteroid that exerts its therapeutic effect by reducing inflammation. It binds to glucocorticoid receptors in cells, suppressing the production of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes, thereby alleviating symptoms associated with inflammatory conditions [8].

2. Are there significant differences between beclomethasone dipropionate and other inhaled corticosteroids? While all inhaled corticosteroids share a common mechanism of action, differences exist in their potency, pharmacokinetic profiles (absorption, distribution, metabolism, and excretion), and local side effect profiles (e.g., oral candidiasis, dysphonia). Beclomethasone dipropionate is generally considered a medium-potency inhaled corticosteroid [6].

3. What are the most common side effects associated with inhaled beclomethasone dipropionate? The most common side effects of inhaled beclomethasone dipropionate include oral candidiasis (thrush), dysphonia (hoarseness), and cough. These are often minimized by rinsing the mouth after inhalation and using appropriate inhalation techniques [8].

4. Can beclomethasone dipropionate monohydrate be used in combination with other respiratory medications? Yes, beclomethasone dipropionate monohydrate is frequently used in combination therapies. It is commonly co-formulated with long-acting beta-agonists (LABAs) for the maintenance treatment of asthma and COPD. It can also be used with short-acting bronchodilators as needed [6].

5. What is the typical duration of treatment for conditions treated with beclomethasone dipropionate monohydrate? Treatment duration is condition-dependent and determined by a healthcare professional. For chronic conditions like asthma and COPD, it is typically a long-term maintenance therapy used daily to control inflammation and prevent exacerbations. For allergic rhinitis, treatment may be intermittent or seasonal [1, 2].

Citations

[1] Global Asthma Report 2022. (2022). Global Initiative for Asthma. [2] World Allergy Organization. (2023). Allergic Rhinitis. World Allergy Organization. [3] GSK plc. (2023). Annual Report and Financial Statements 2022. [4] MarketsandMarkets. (2023). Inhaler Devices Market - Global Forecast to 2028. [5] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from fda.gov [6] Global Initiative for Asthma. (2023). GINA Report: Global Strategy for Asthma Management and Prevention. [7] European Medicines Agency. (n.d.). Information for pharmaceutical companies: Scientific advice and protocol assistance. Retrieved from ema.europa.eu [8] F. L. J. M. van den Bemt & P. J. M. van den Bemt. (2017). Inhaled corticosteroids: Efficacy, safety and inhalation technique. Current Opinion in Allergy and Clinical Immunology, 17(1), 11-17.